Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$11.18−0.46 (-3.95%)
Close on Nov 19, 2026Market cap $1.45BP/E –Yield –
Mesoblast gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2026 it was $103.58M, up 758.3% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $103.58M | +758.3% |
| FY2025 | Jun 30, 2025 | $12.07M | +104.5% |
| FY2024 | Jun 30, 2024 | $5.90M | -21.3% |
| FY2023 | Jun 30, 2023 | $7.50M | – |
See a number that looks wrong?